Measuring the rate of progression of Parkinson's disease over a 5-year period with β-CIT SPECT

被引:62
作者
Pirker, W
Holler, I
Gerschlager, W
Asenbaum, S
Zettinig, G
Brücke, T
机构
[1] Univ Vienna, Dept Neurol, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Nucl Med, Vienna, Austria
[3] Wilhelminenspital Stadt Wien, Dept Neurol, Vienna, Austria
关键词
Parkinson's disease; disease progression; I-123]beta-CIT; single photon emission computerized tomography; (SPECT);
D O I
10.1002/mds.10531
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recent imaging studies suggest a rapid degeneration of the dopaminergic system in early Parkinson's disease (PD), followed by a slowing of the degenerative process in advanced disease. In the present study, a group of early-stage PD patients underwent three sequential [I-123] beta-CIT SPECT studies to assess the decline of striatal dopamine transporter binding over a 5-year period. Twenty-one of a cohort of 24 early PD patients who participated in an earlier longitudinal beta-CIT SPECT imaging study [Mov Disord 2002; 17:45-53] were included. Scan intervals were 26 +/- 11 months (scan 1-2) and 38 +/- 15 months (scan 2-3), respectively. The relative annual rate of decline of striatal beta-CIT binding from age-expected normal values at the time of Scan 1 was used as primary outcome variable. The relative annual decline of striatal binding from Scan I to Scan 2 (4.5 +/- 4.6%) and from Scan 2 to Scan 3 (3.0 +/- 3.0%) was not significantly different. The non-significant difference in progression rate was due mainly to the rapid early decline of striatal binding in 1 patient who subsequently developed a severe dysexecutive dementia syndrome. These data are not suggestive of substantial change in the course of dopaminergic degeneration in PD within the first 5 to 7 years after symptom onset. (C) 2003 Movement Disorder Society.
引用
收藏
页码:1266 / 1272
页数:7
相关论文
共 39 条
[1]  
Asenbaum S, 1997, J NUCL MED, V38, P1
[2]  
Benamer HTS, 2000, MOVEMENT DISORD, V15, P692, DOI 10.1002/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO
[3]  
2-V
[4]   DOES LONG-TERM AGGRAVATION OF PARKINSONS-DISEASE RESULT FROM NONDOPAMINERGIC LESIONS [J].
BONNET, AM ;
LORIA, Y ;
SAINTHILAIRE, MH ;
LHERMITTE, F ;
AGID, Y .
NEUROLOGY, 1987, 37 (09) :1539-1542
[5]   Imaging end points for monitoring neuroprotection in Parkinson's disease [J].
Brooks, DJ .
ANNALS OF NEUROLOGY, 2003, 53 :S110-S118
[6]   DIFFERING PATTERNS OF STRIATAL F-18 DOPA UPTAKE IN PARKINSONS-DISEASE, MULTIPLE SYSTEM ATROPHY, AND PROGRESSIVE SUPRANUCLEAR PALSY [J].
BROOKS, DJ ;
IBANEZ, V ;
SAWLE, GV ;
QUINN, N ;
LEES, AJ ;
MATHIAS, CJ ;
BANNISTER, R ;
MARSDEN, CD ;
FRACKOWIAK, RSJ .
ANNALS OF NEUROLOGY, 1990, 28 (04) :547-555
[7]   Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years [J].
Chouker, M ;
Tatsch, K ;
Linke, R ;
Pogarell, O ;
Hahn, K ;
Schwarz, J .
NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (06) :721-725
[8]  
Fahn S., 1987, RECENT DEV PARKINSON, P153
[9]   AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY [J].
FEARNLEY, JM ;
LEES, AJ .
BRAIN, 1991, 114 :2283-2301
[10]   Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging [J].
Frey, KA ;
Koeppe, RA ;
Kilbourn, MR ;
VanderBorght, TM ;
Albin, RL ;
Gilman, S ;
Kuhl, DE .
ANNALS OF NEUROLOGY, 1996, 40 (06) :873-884